Our goal at JWM Neurology is to offer comprehensive care for patients who have suspected or confirmed multiple sclerosis (MS). All of our neurologists are dedicated to diagnosing and treating MS as well as helping patients maintain their daily activities and improve their lives.
Over the past several years, our practice has become very active in clinical research. Through the work of neurologist Craig E. Herrman, MD, and his research staff, JWM Neurology has a dedicated Research Division that offers numerous clinical trials for neurological conditions and sleep disorders. Regardless of the type of MS that patients have, there are various trials available. Patients who do not currently qualify for one of our trials will be given the option to be put on a list for future opportunities.
JWM Neurology has several studies ongoing. These encompass patients with relapsing remitting multiple sclerosis as well as those with a first clinical event – or even a more progressive course of the disease. Studies range from new disease-modifying agents to medications that will improve the everyday symptoms seen in MS. Our Clinical Research Manager, Kristina Cleveland, along with her staff, is dedicated to patient care and continuing to expand our JWM Neurology research opportunities.
The treatment of multiple sclerosis has become increasingly challenging over the past several years. There are multiple treatment options currently available in the general market and in research studies as well as those currently awaiting FDA approval. Physicians treating MS will need to be able to balance the use of reliable "older" medicines with those coming to market.
It is an exciting time in the field of multiple sclerosis. Injections, oral medications, monthly infusions and even yearly infusions are potential options. However, with each mode of therapy there are clear drawbacks. Through the collective expertise of our physicians at JWM Neurology, we are able to educate patients and make informed, joint decisions on the best treatment to pursue. Each patient will likely be different, and the treatment will not only differ based on potential side effects, but also on lifestyle and the particular variety of multiple sclerosis.
Craig E. Herrman, MD, is an Indiana native. He graduated with a Bachelor of Science from Purdue University with high distinction. It was at Purdue that he became intrigued with neuroscience. He attended Indiana University School of Medicine and graduated at the top of his class. He then completed his Neurology residency at University of Rochester in upstate New York. There, he was able to work under several experts in Multiple Sclerosis and neuroimmunology. Before moving back to Indiana, he completed an extra year of training in a Fellowship, specializing in neuromuscular disease.
Dr. Herrman has practiced at JWM Neurology since 2005. He has been the Principle Investigator for over 30 clinical trials, most involving the treatment of Multiple Sclerosis. These have included trials on nearly all of the newly-approved medications over the past decade, and many which may be approved in the short-term future. This provides him an important level understanding and experience with these new medications.
Patients with a first diagnosis of multiple sclerosis or suspected MS have many questions. The National Multiple Sclerosis Society has a very informative website which answers many of those questions (see the “Q&A” section on their homepage).